Novartis drops TREM2 antibody in ALS after Phase 2 miss
Novartis discontinued VHB937, a TREM2 antibody for ALS, after a Phase 2 trial missed its primary endpoint. The trial tested the drug in 251 early-stage ALS patients. Novartis did not release numerical data, with detailed findings expected in December. The setback follows recent failures in Novartis' pipeline, including pelacarsen and del-desiran. ALS drug development has seen many failures, with no current treatments stopping or reversing the disease.
How this was made
The 30-second read
Why it matters
The miss may trigger a downgrade or price target reduction, reinforcing a negative bias on the stock.
Market read
The announcement adds to a series of setbacks for Novartis' neurodegeneration programs, likely weighing on the stock and sector sentiment.
What to watch
Potential pipeline synergies with Novartis' Avidity Biosciences acquisition and upcoming Phase 2 Alzheimer’s data could offset short‑term pain.
Background
Novartis' neurology portfolio has faced a string of recent failures, including pelacarsen and del-desiran, increasing pressure on its pipeline.
Ticker impact
Novartis announced its Phase 2 ALS antibody VHB937 missed its primary endpoint, a fresh clinical‑trial failure for the company.
Potential short‑term downside pressure on NVS stock.
Phase 2 miss signals limited near‑term upside and may trigger re‑rating by analysts.
Market effects
Highlights challenges in ALS drug development, may dampen sentiment for biotech firms pursuing neurodegeneration targets.
Limited to US and European biotech markets.
Adds to broader caution on late‑stage neurology trials worldwide.
Counterpoint
Some investors may view the miss as a buying opportunity if the stock is oversold after multiple setbacks.
Key entities
- companyNovartis
Swiss pharmaceutical giant developing the VHB937 ALS antibody.
